Analyst Price Targets — CGON
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 14, 2026 1:18 pm | — | Truist Financial | $82.00 | $70.01 | TheFly | CG Oncology price target raised to $82 from $77 at Truist |
| May 11, 2026 1:29 pm | — | RBC Capital | $81.00 | $70.91 | TheFly | CG Oncology price target raised to $81 from $79 at RBC Capital |
| May 11, 2026 11:50 am | — | Wedbush | $80.00 | $69.62 | TheFly | CG Oncology price target raised to $80 from $77 at Wedbush |
| April 27, 2026 12:09 pm | — | RBC Capital | $79.00 | $69.42 | TheFly | CG Oncology price target raised to $79 from $73 at RBC Capital |
| March 26, 2026 1:03 pm | — | UBS | $90.00 | $66.67 | TheFly | CG Oncology price target raised to $90 from $60 at UBS |
| February 10, 2026 2:19 pm | — | Truist Financial | $75.00 | $53.39 | TheFly | CG Oncology price target raised to $75 from $66 at Truist |
| January 21, 2026 11:34 am | — | RBC Capital | $73.00 | $54.69 | TheFly | CG Oncology price target raised to $73 from $61 at RBC Capital |
| January 16, 2026 11:55 am | Kelsey Goodwin | Piper Sandler | $70.00 | $53.07 | TheFly | CG Oncology price target raised to $70 from $55 at Piper Sandler |
| January 12, 2026 11:19 am | — | Goldman Sachs | $82.00 | $54.20 | TheFly | CG Oncology price target raised to $82 from $55 at Goldman Sachs |
| January 9, 2026 7:49 pm | — | Morgan Stanley | $93.00 | $54.20 | TheFly | CG Oncology price target raised to $93 from $89 at Morgan Stanley |
Latest News for CGON
CGON climbs as cretostimogene nears a planned 2026 BLA filing, posts encouraging phase II data. It maintains a cash position that supports operations through 2029.
CG Oncology NASDAQ: CGON Chief Executive Officer Arthur outlined the company's upcoming clinical and regulatory milestones for cretostimogene during a presentation at the Goldman Sachs Global Healthcare Conference, emphasizing data readouts, a potential filing and commercial preparation in non-muscle invasive bladder cancer, or NMIBC.
CG Oncology, Inc. (CGON) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
CG Oncology NASDAQ: CGON is focused on advancing cretostimogene, an oncolytic immunotherapy for non-muscle invasive bladder cancer, Chief Executive Officer Arthur Kuan said during a discussion at the Jefferies Global Healthcare Conference in New York.
DALLAS, May 28, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentations at the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference this month. The details of the upcoming events are as follows:
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CGON.
U.S. House Trading
No House trades found for CGON.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.